Takeda Pharmaceutical (TAK) EBITDA (2009 - 2026)
Takeda Pharmaceutical (TAK) EBITDA from Dec 31, 2009 to Mar 31, 2026. The TTM Takeda Pharmaceutical (TAK) EBITDA is $9.45B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Takeda Pharmaceutical (TAK) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +26.01% |
| 3 Years TTM | +1.73% |
| 5 Years TTM | +0.48% |
| 10 Years TTM | +13.09% |
| All Time TTM | +3.11% |
Annual EBITDA change of Takeda Pharmaceutical (TAK)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $0 | N/A |
| 2025 | $0 | N/A |
| 2024 | $0 | N/A |
| 2023 | $0 | N/A |
| 2022 | $0 | -100.00% |
| 2021 | $8.88B | +42.46% |
| 2020 | $6.24B | +49.08% |
| 2019 | $4.18B | +23.48% |
| 2018 | $3.39B | +27.05% |
| 2017 | $2.67B | -14.28% |
| 2016 | $3.11B | +551.75% |
| 2015 | $477M | -86.62% |
| 2014 | $3.57B | -5.32% |
| 2013 | $3.77B | -23.53% |
| 2012 | $4.93B | -14.53% |
| 2011 | $5.77B | +1.26% |
| 2010 | $5.69B | +109.89% |
| 2009 | $2.71B | N/A |
Comparison Takeda Pharmaceutical (TAK) five years EBITDA CAGR with competitors
Takeda Pharmaceutical (TAK) five years EBITDA CAGR is 0.48%.